GIM
ARCT icon

Granahan Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

Granahan Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-86,416
Closed -$2.01M – 181
2024
Q3 		$2.01M Sell
86,416
-258,133
-75% -$5.52M 0.08% 171
2024
Q2 		$8.39M Buy
344,549
+8,402
+2% +$255K 0.34% 88
2024
Q1 		$11.4M Sell
336,147
-114,219
-25% -$4.05M 0.4% 74
2023
Q4 		$14.2M Buy
450,366
+51,504
+13% +$1.22M 0.47% 67
2023
Q3 		$10.2M Buy
+398,862
New +$12.3M 0.36% 85
2022
Q2 		– Sell
-64,851
Closed -$1.75M – 176
2022
Q1 		$1.75M Buy
64,851
+9,446
+17% +$241K 0.04% 169
2021
Q4 		$2.05M Sell
55,405
-17,772
-24% -$724K 0.04% 176
2021
Q3 		$3.5M Buy
+73,177
New +$3.28M 0.07% 170

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Granahan Investment Management's ARCT Position: Q4 2024 in Review

Granahan Investment Management sold out of Arcturus Therapeutics (ARCT) in Q4 2024, closing a stake of 86,416 shares — an estimated $2.01M sold.

Granahan Investment Management first reported a position in ARCT in Q3 2021 and held it in 8 quarters. The position peaked at $14.2M in Q4 2023. 147 funds tracked by Wall St. Rank hold ARCT as of Q4 2024.

  • Granahan Investment Management reported no remaining Arcturus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Granahan Investment Management sold 86,416 Arcturus Therapeutics shares in Q4 2024, an estimated $2.01M.
  • Granahan Investment Management first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 8 quarters.
  • Granahan Investment Management's Arcturus Therapeutics position peaked at $14.2M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2024.

Based on Granahan Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.